Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay

Yeh, Jun-Jun; Syue, Shih-Hueh; Sun, Yi-Fun; Yeh, Yi‐Ting; Zheng, Ya-Chi; Lin, Cheng‐Li; Hsu, Chung Y.; Kao, Chia Hung

doi:10.3390/biomedicines10061290

Cited by 1 publication

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, when we interpret the FQs on the risk of cancer in the ILD cohort, confounding factors, such as drug resistance and resistance-related higher medical services, must be considered. 7 This result warrants further large-scale randomized control trials.…”

Section: Fq Sensitivity To Lung Infection or Intestine Infectionmentioning

confidence: 88%

“…[62][63][64] Therefore, the results of our study may infer the trend of research on the relationship between virus infection, cancer, and ILD in the coronavirus era. 7…”

Section: Strengthmentioning

confidence: 99%

“…Fourth, different study designs would be needed to determine the role of other drugs in the risk of cancer. 7 Fifth, the current study was based on patient data between 2000 to 2012 and follow up to 2013, which was more than 10 years ago from now. However, the lung cancer ranks the most popular cancer in the world at present.…”

Section: Limitationsmentioning

confidence: 99%

“…2,6 Therefore, ILD with virus infection (ILD cohort) and the impact of the virus on cancer remain an important topic in the coronavirus pandemic. 7 Fluoroquinolones (FQs) are indicated for the treatment of urinary tract infections, including complicated urinary tract infections (e.g., pelvic in ammatory disease [PID]), complicated pyelonephritis, chronic bacterial prostatitis, intra-abdominal infections, and lower respiratory tract infections, including acute exacerbations of COPD, nosocomial pneumonia, and perhaps TB, sinusitis, skin, soft tissue (e.g., gout with bacterial infection), bone and joint infections (e.g., periodontal diseases, gout with bacterial infection), and febrile neutropenia (e.g., DM). Worldwide, FQs use is increasing and has been associated with rising rates of resistance.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The effect of fluoroquinolones on the cancer development in patients with interstitial lung disease and virus infection

Yeh,

Sun,

Tang

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

The virus increased risk of cancer and fluoroquinolones (FQs) could induce the interstitial lung disease (ILD) such as acute interstitial pneumonitis. The effects of FQs on the risk of cancer in patients having theILD concurrent with virus infection (ILD cohort) based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) is to be determined. The propensity score was calculated based on age, sex, index date, and medications of these comorbidities. Through the January 2000 to December 2013, the ILD cohort with FQs use (FQs cohort, N = 3,264) and those in the ILD cohort without FQs use (non-FQs cohort, N = 3,264) enter into study. Cox proportional regression with time-dependent exposure covariates was used to analyze the cumulative incidence of cancer. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for cancer were determined after controlling for sex, age, medications (anti-inflammatory drugs, immunosuppressants), and comorbidities, as well as the use of FQs. Compared with the non-FQs cohort, the FQs cohort had aHRs (95% CIs) for cancer, colorectal cancer, lung cancer, and prostate cancer were 0.70 (0.59–0.83), 0.56 (0.37–0.85), 0.56 (0.38–0.85), and 2.39 (1.27–4.49) respectively. For patients with a single use of FQ>4≤ 15 days/ >15 days, the aHRs (95% CIs) were 0.50 (0.32–0.78)/1.83(0.71–4.70), 0.47 (0.31–0.73)/ 2.08 (0.97-4.48), and 1.94 (1.01–3.74)/ 12.1 (4.73–31.1) for colorectal, lung, and prostate cancers, respectively. The trend of the increase of the value of the aHR was found in these three cancers. For the patients with the cumulative daily dose FQ>4000mg ≤ 15 000mg/ >15 000mg, the similar trend was found also.Meanwhile, the use of FQs >4 ≤15 days (<cDDD, >4000mg ≤15000mg) was associated with a lower aHR for colorectal cancer and lung cancer in selected cases (drug sensitive). The use of the FQs >15 days(>cDDD15000 mg) was with a higher aHR for cancers such as prostate cancer (drug resistance). Perhaps, the FQs with drug sensitive for colorectal cancer and lung cancer may play an auxiliary role for prevention of these two cancers. Meanwhile, the FQs with drug resistance may not play a role for prevention of the prostate cancer. However, confounding factors such as drug resistance and a higher rate of medical services must be considered in the prostate cancer cohort.

show abstract

Section: Fq Sensitivity To Lung Infection or Intestine Infectionmentioning

confidence: 88%

“…[62][63][64] Therefore, the results of our study may infer the trend of research on the relationship between virus infection, cancer, and ILD in the coronavirus era. 7…”

Section: Strengthmentioning

confidence: 99%

Section: Limitationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of fluoroquinolones on the cancer development in patients with interstitial lung disease and virus infection

Yeh,

Sun,

Tang

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay

Cited by 1 publication

References 59 publications

The effect of fluoroquinolones on the cancer development in patients with interstitial lung disease and virus infection

The effect of fluoroquinolones on the cancer development in patients with interstitial lung disease and virus infection

Contact Info

Product

Resources

About